Taken together, although Menin inhibition alone impairs leukemic progression of NUP98-r/FLT3-ITD+ AML, the combination of Menin and FLT3 inhibitors increases their antileukemic efficacy in a synergistic manner. The gene discussed is FLT3; the disease is acute myeloid leukemia.